| Literature DB >> 34113396 |
Wenpin Cai1, Jingzhang Ji2, Biting Wu2, Kaixuan Hao2, Ping Ren2, Yu Jin2, Lihong Yang2, Qingchao Tong2, Zhifa Shen2.
Abstract
Increasing evidence suggest that hepatocellular carcinoma (HCC) HCCLM3 cells initially develop pseudopodia when they metastasize, and microRNAs (miRNAs/miRs) and circular RNAs (circRNAs) have been demonstrated to serve important roles in the development, progression and metastasis of cancer. The present study aimed to isolate the cell bodies (CBs) and cell protrusions (CPs) from HCCLM3 cells, and screen the miRNAs and circRNAs associated with HCC infiltration and metastasis in CBs and CPs. The Boyden chamber assay has been confirmed to effectively isolate the CBs and CPs from HCCLM3 cells via observation of microtubule immunofluorescence, DAPI staining and nuclear protein H3 western blotting. Following high-throughput sequencing of the successfully isolated CBs and CPs, 64 pairs of miRNAs, including 23 pairs of upregulated genes and 41 pairs of downregulated genes, and 260 sets of circRNAs, including 127 upregulated genes and 133 downregulated genes, were significantly differentially expressed, using the following criteria: HP/HB ratio, fold change ≥|1.5|, P<0.05). PCR analysis verified that changes in the expression levels of hsa-let-7a-5p, hsa-let-7c-3p, hsa-miR-30c-5p, hsa_circ_0059580, hsa_circ_0067475, hsa_circ_0002100 and hsa_circ_00072309 were consistent with the sequencing results. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to analyze the functions and roles of the differentially expressed miRNAs and circRNAs. The interaction maps between miRNAs and circRNAs were constructed, and signaling pathway maps were analyzed to determine the molecular mechanism and regulation of the differentially expressed miRNAs and circRNAs. Taken together, the results of the present study suggest that the Boyden chamber assay can be used to effectively isolate the somatic CBs and CPs of HCC, which can be used to screen the miRNAs and circRNAs associated with invasion and metastasis of HCC. Copyright: © Cai et al.Entities:
Keywords: Boyden chamber assay; HCCLM3 cells; cell body; cell protrusion; circular RNA; hepatocellular carcinoma; metastasis; microRNA
Year: 2021 PMID: 34113396 PMCID: PMC8185705 DOI: 10.3892/ol.2021.12829
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Figure 1.Segregation of HCCLM3 cell bodies and cell protrusions via the Boyden chamber assay.
Primer sequences used for quantitative PCR.
| ID | Forward primer ( | Reverse primer ( |
|---|---|---|
| hsa-miR-7-1-3p | CGGGCCAACAAATCACAGTC | CAGCCACAAAAGAGCACAAT |
| hsa-miR-374b-3p | CGCCGCTTAGCAGGTTGTAT | CAGCCACAAAAGAGCACAAT |
| hsa-miR-340-5p | GCGGCTTATAAAGCAATGAG | CAGCCACAAAAGAGCACAAT |
| hsa-miR-17-5p | CGGGCCAAAGTGCTTACAGTG | CAGCCACAAAAGAGCACAAT |
| hsa-miR-3074-3p | CGCCGGATATCAGCTCAGTA | CAGCCACAAAAGAGCACAAT |
| hsa-miR-186-5p | GCGGCCAAAGAATTCTCCTT | CAGCCACAAAAGAGCACAAT |
| hsa-miR-21-3p | CGGGCCAACACCAGTCGAT- | CAGCCACAAAAGAGCACAAT |
| hsa-miR-146b-3p | CGCCGTGCCCTGTGGACTCA | CAGCCACAAAAGAGCACAAT |
| hsa-let-7f-5p | GCGGCTGAGGTAGTAGATTG | CAGCCACAAAAGAGCACAAT |
| hsa-miR-26a-2-3p | CGCCGCCTATTCTTGATTAC | CAGCCACAAAAGAGCACAAT |
| hsa-miR-423-5p | GCGGTGAGGGGCAGAGAGCG | CAGCCACAAAAGAGCACAAT |
| hsa-miR-7-5p | CGGGCTGGAAGACTAGTGATT | CAGCCACAAAAGAGCACAAT |
| hsa-miR-423-3p | CGCCGAGCTCGGTCTGAGGCC | CAGCCACAAAAGAGCACAAT |
| hsa-miR-191-5p | GCGGCCAACGGAATCCCAAAA | CAGCCACAAAAGAGCACAAT |
| hsa-miR-744-5p | CGGGCTGCGGGGCTAGGGCT | CAGCCACAAAAGAGCACAAT |
| hsa-miR-193a-3p | CGCCGAACTGGCCTACAAAG | CAGCCACAAAAGAGCACAAT |
| hsa-miR-24-3p | GCGGCTGGCTCAGTTCAGCA | CAGCCACAAAAGAGCACAAT |
| hsa-miR-3529-3p | CGGGAACAACAAAATCACTAG | CAGCCACAAAAGAGCACAAT |
| hsa-miR-574-5p | CGCCGTGAGTGTGTGTGTGTG | CAGCCACAAAAGAGCACAAT |
| hsa-miR-20a-5p | CGCCGTAAAGTGCTTATAGTG | CAGCCACAAAAGAGCACAAT |
| hsa-let-7d-3p | CGGGCCTATACGACCTGCTG | CAGCCACAAAAGAGCACAAT |
| hsa-let-7f-2-3p | CGCCGCTATACAGTCTACTG | CAGCCACAAAAGAGCACAAT |
| hsa_circ_0002029 | CCTCCCATGAAAGTGTTAATG | CAGTAGCTCCACTGCCTTTTG |
| hsa_circ_0002100 | GTTTGCAGAGTCCAGAATTTG | ACCAGTATATCATCCTGCTT- |
| hsa_circ_0003656 | GATTACAGGCTGGAGCCACA | CTTGGTTGTTCACTCCCTGAG |
| hsa_circ_0003789 | CTTGCCAGTGAACTGGAAATC | CAAACACCTCTTTGGAATGTCC |
| hsa_circ_0007429 | TGGGAACATGCACAGTGTCA | CTGACCCACTGATAGACTATG |
| hsa_circ_0008797 | CTGCTGGAGTATACACCAACT | CTGCTGGAGTATACACCAACT |
| hsa_circ_0059580 | CTGAACTATGTCATGGGATTCA | CATTGCATTCTTTTGCTGAC |
| hsa_circ_0067475 | GGCTCTCCTTCCAAACCATG | CTGAAGTAGTAACTCCAACCT |
| hsa_circ_0087200 | CTGAACGTATTCCATGAACGA | CTTCACTCTAGAATACTGTAC |
| β-actin | CATGTACGTTGCTATCCAGGC | CTCCTTAATGTCACGCACGAT |
Figure 2.Validation for the isolation of mRNA from the cell bodies and cell protrusions of HCCLM3 cells. (A) Immunofluorescence analysis of HCCLM3 cells. (B) EtBr staining of HCCLM3 cells. (C and D) Validation for immunofluorescence and western blot analyses of Boyden petri dish isolation.
Figure 3.RNA purity and quality testing. (A) Agarose gel electrophoresis of RNA. (B-D) Peaks of the ladder.
Figure 4.Identification of differentially expressed miRNA and circRNA profiles. (A) Distribution of small RNA length. (B) Annotation of small RNA classification. (C) Comparison of cell bodies and cell protrusions in miRNAs. (D) Gene Ontology and (E) Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. miRNA, microRNA; circRNA, circular RNA.
Figure 5.Identification of differentially expressed circRNA profiles. (A) Length distribution of circRNA. (B) Length distribution of cytoplasmic circRNA. (C) Length distribution of circRNA. (D) cyclic RNA volcano comparison. (E) HP and HB comparatively significant differentially expressed circular RNA heat map. (F) Histogram of HPvsHB_KEGG pathway enrichment (G) KEGG pathway enrichment dot plot. (H) Gene Ontology enrichment map. CircRNA, circular RNA.
Upregulated and downregulated genes.
| hsa_circbase_ID | Fold change | P-value | hsa_circbase_ID | Fold change | P-value |
|---|---|---|---|---|---|
| hsa_circ_0087200 | 67.60346424 | 0.006742853 | hsa_circ_0091124 | −83.50491956 | 0.000497791 |
| hsa_circ_0007090 | 67.60346424 | 0.006742853 | hsa_circ_0008181 | −83.50491956 | 0.000497791 |
| hsa_circ_0001487 | 67.60346424 | 0.006742853 | hsa_circ_0003600 | −83.50491956 | 0.000497791 |
| hsa_circ_0001264 | 67.60346424 | 0.006742853 | hsa_circ_0007928 | −71.71850248 | 0.001077943 |
| hsa_circ_0058039 | 67.60346424 | 0.006742853 | hsa_circ_0067475 | −71.71850248 | 0.001077943 |
| hsa_circ_0024960 | 61.54860385 | 0.009205770 | hsa_circ_0046029 | −71.71850248 | 0.001077943 |
| hsa_circ_0087357 | 55.49374347 | 0.012719766 | hsa_circ_0026297 | −71.71850248 | 0.001077943 |
| hsa_circ_0008058 | 55.49374347 | 0.012719766 | hsa_circ_0007827 | −71.71850248 | 0.001077943 |
| hsa_circ_0070680 | 55.49374347 | 0.012719766 | hsa_circ_0018478 | −71.71850248 | 0.001077943 |
| hsa_circ_0008027 | 55.49374347 | 0.012719766 | hsa_circ_0004907 | −71.71850248 | 0.001077943 |
| hsa_circ_0005775 | 55.49374347 | 0.012719766 | hsa_circ_0001571 | −59.93208540 | 0.002458840 |
| hsa_circ_0023182 | 55.49374347 | 0.012719766 | hsa_circ_0075158 | −59.93208540 | 0.002458840 |
| hsa_circ_0000126 | 55.49374347 | 0.012719766 | hsa_circ_0001398 | −59.93208540 | 0.002458840 |
| hsa_circ_0004994 | 49.43888308 | 0.017811177 | hsa_circ_0002693 | −59.93208540 | 0.002458840 |
| hsa_circ_0006348 | 49.43888308 | 0.017811177 | hsa_circ_0002102 | −59.93208540 | 0.002458840 |
| hsa_circ_0003789 | 49.43888308 | 0.017811177 | hsa_circ_0058055 | −59.93208540 | 0.002458840 |
| hsa_circ_0056280 | 49.43888308 | 0.017811177 | hsa_circ_0006877 | −59.93208540 | 0.002458840 |
| hsa_circ_0008520 | 49.43888308 | 0.017811177 | hsa_circ_0005804 | −59.93208540 | 0.002458840 |
| hsa_circ_0042880 | 49.43888308 | 0.017811177 | hsa_circ_0032396 | −59.93208540 | 0.002458840 |
| hsa_circ_0008926 | 49.43888308 | 0.017811177 | hsa_circ_0025822 | −59.93208540 | 0.002458840 |
Circ, circular.
Figure 6.CircRNA_miRNA interaction network diagram. (A) CircRNA miRNA interaction network. (B) circRNA and miRNA interaction network diagram (C) miRNA-7-5P binding site. CircRNA, circular RNA; miRNA, microRNA.7
Canonical pathway analysis.
| Ingenuity canonical pathways | Log (P-value) | Ratio | z-score | Molecules |
|---|---|---|---|---|
| Oxidative phosphorylation | 12.30 | 0.327 | #NUM! | NDUFA4, SDHB, COX7B, ATP5G1, UQCRH, COX5B, NDUFB5, COX8A, ATP5L, ATP5S, ATP5E, NDUFB3, NDUFA2, ATP5J2, UQCRFS1, NDUFB6, ATP5I, NDUFAB1, COX7B2, ATP5O, NDUFB1, UQCR11, COX11, NDUFS8, NDUFA11, COX6B2, NDUFB7, COX7A2, SDHD, CYCS, CYB5A, NDUFS3, NDUFB2, UQCRQ |
| Mitochondrial dysfunction | 8.63 | 0.230 | #NUM! | NDUFA4, ATP5G1, SDHB, COX7B, UQCRH, COX5B, NDUFB5, COX8A, ATP5L, ATP5S, ATP5E, NDUFB3, NDUFA2, PARK7, ATP5J2, NDUFB6, UQCRFS1, PRKN, ATP5I, NDUFAB1, COX7B2, ATP5O, NDUFB1, UQCR11, FIS1, PRDX3, COX11, NDUFS8, NDUFA11, COX6B2, NDUFB7, COX7A2, SDHD, CYCS, CYB5A, NDUFS3, NDUFB2, UQCRQ |
| EIF2 signaling | 8.37 | 0.208 | 2.294 | RPS3A, RPL22L1, RPLP2, RPL39, RPL26, RPL35A, KLB, RPS28, RPS7, VEGFA, RPL35, RPS20, RPS13, IGF1R, RPL21, RPL39L, IRS2, RPL36, RPS12, RPS5, RPL32, RPS19, RPL34, RPS8, RPL17, RPS10, RPL29, EIF2B3, RPS21, RPS29, RPL10A, RPL9, RPL27, RPS16, RPS26, RPL26L1, EIF3I, RPS27A, PIK3CD, RPS15A, RPS25, INSR, RPSA, RPS14 |
| Regulation of eIF4 and p70S6K signaling | 4.44 | 0.182 | −2.449 | RPS3A, KLB, EIF4EBP1, RPS28, RPS7, ITGA3, RPS20, RPS13, IRS2, RPS5, RPS12, RPS19, ITGA2, RPS8, RPS10, ITGA5, EIF2B3, RPS21, RPS29, RPS16, RPS26, EIF3I, RPS27A, RPS15A, PIK3CD, RPS25, RPS14, RPSA |
| Prostanoid biosynthesis | 3.49 | 0.556 | #NUM! | PTGIS, PTGES, PTGS1, PTGS2, PTGDS |
| Vitamin C transport | 3.15 | 0.400 | #NUM! | SLC2A1, TXN, NXN, GSTO2, SLC2A3, GSTO1 |
| mTOR signaling | 2.95 | 0.147 | −0.707 | RPS3A, KLB, EIF4EBP1, RPS28, VEGFA, RPS7, RPS20, RPS13, RHOD, RPS6KB2, IRS2, RPS12, RPS5, RPS19, RPS8, RPS10, RPS21, RPS29, RPS6KA6, RPS16, RPS26, EIF3I, RPS27A, RPS15A, PIK3CD, RPS25, INSR, RPSA, RPS14 |
| Pyrimidine deoxyribonucleotides | 2.78 | 0.304 | #NUM! | TYMS, NME3, NME1, NME2, AK4, DTYMK, AK7 |
eIF4, eukaryotic initiation factor 4; mTOR, target of rapamycin.
Functional and disease correlation analyses.
| Categories | Disease or function annotation | P-value | Predicted activation state | Activation z-score | Molecules |
|---|---|---|---|---|---|
| Cellular movement | Migration of brain cancer cell lines | 0.001240 | Decreased | −3.482 | 22 |
| Cellular movement | Cell movement of brain cancer cell lines | 0.002400 | Decreased | −3.619 | 24 |
| Cellular movement | Cell movement of tumor cell lines | 0.007710 | Decreased | −4.666 | 123 |
| Cellular movement | Migration of cells | 0.008930 | Decreased | −4.841 | 160 |
| Cellular movement | Cell movement | 0.004350 | Decreased | −5.188 | 183 |
| Cancer, organismal injury and abnormalities | Genitourinary tumor | 0.000247 | Increased | 2.186 | 823 |
| Cancer, organismal injury and abnormalities | Urogenital cancer | 0.000637 | Increased | 2.219 | 804 |
| Cancer, organismal injury and abnormalities, renal and urological disease | Renal cancer | 0.004210 | Increased | 2.000 | 150 |
| Cancer, organismal injury and abnormalities, renal and urological disease | Renal cancer and tumors | 0.00514 | Increased | 2.000 | 152 |
| Cancer, organismal injury and abnormalities, renal and urological disease | Urinary tract cancer | 0.00855 | Increased | 2.000 | 182 |
Figure 7.Identification of differentially expressed miRNA and circRNA profiles. (A) Transcriptional regulation analysis: (A) Decreased TGFB1 signaling, (B) decreased TNF signaling and (C) increased SPDEF signaling. (D) Network interworking_ID_1. TGFB1, transforming growth factor-β1; TNF, tumor necrosis factor.
Upregulation and downregulation of the 20 genes.
| miRNA ID | Count (HB) | Count (HP) | TPM (HB) | TPM (HP) | log2 ratio (HP/HB) | Upregulation (Up) or downregulation (Down) (HP/HB) |
|---|---|---|---|---|---|---|
| hsa-miR-4742-3p | 0 | 45 | 0.001 | 2.060 | 11.008 | Up |
| hsa-miR-26a-1-3p | 9036 | 412298 | 511.220 | 18910.310 | 5.209 | Up |
| hsa-miR-17-5p | 210 | 7649 | 11.880 | 350.830 | 4.884 | Up |
| hsa-miR-30c-5p | 808 | 23968 | 45.710 | 1099.310 | 4.587 | Up |
| hsa-miR-548av-3p | 1 | 30 | 0.0600 | 1.380 | 4.523 | Up |
| hsa-miR-7-1-3p | 6539 | 172266 | 369.950 | 7901.090 | 4.416 | Up |
| hsa-miR-3609 | 2 | 42 | 0.110 | 1.930 | 4.133 | Up |
| hsa-miR-338-5p | 2 | 31 | 0.110 | 1.420 | 3.690 | Up |
| hsa-miR-374b-3p | 202 | 2580 | 11.430 | 118.330 | 3.371 | Up |
| hsa-miR-576-5p | 15 | 178 | 0.850 | 8.160 | 3.263 | Up |
| novel_mir29 | 40 | 0 | 2.260 | 0.001 | −11.142 | Down |
| hsa-miR-4750-3p | 33 | 0 | 1.870 | 0.001 | −10.868 | Down |
| hsa-miR-3150a-3p | 17 | 0 | 0.960 | 0.001 | −9.907 | Down |
| hsa-miR-6855-5p | 16 | 0 | 0.910 | 0.001 | −9.830 | Down |
| novel_mir111 | 15 | 0 | 0.850 | 0.001 | −9.731 | Down |
| hsa-miR-6820-3p | 11 | 0 | 0.620 | 0.001 | −9.276 | Down |
| novel_mir27 | 747 | 2 | 42.260 | 0.090 | −8.875 | Down |
| novel_mir47 | 103 | 1 | 5.830 | 0.050 | −6.865 | Down |
| novel_mir57 | 164 | 3 | 9.280 | 0.140 | −6.051 | Down |
| novel_mir109 | 115 | 3 | 6.510 | 0.140 | −5.539 | Down |
miR, microRNA.
Figure 8.Validation for the differentially expressed miRNAs and circRNAs. (A) Comparisons between RNA-Seq and RT-qPCR analysis among the 20 miRNAs. (B) RT-qPCR analysis was performed to detect the relative expression levels of the five circRNAs. (C) Comparison of circRNA expression profiles via RT-qPCR analysis and RNA-Seq. miRNA, microRNA; circRNAs, circular RNA; RNA-Seq, RNA sequencing; RT-qPCR, reverse transcription-quantitative PCR.